John Corkery

6.8k total citations · 2 hit papers
157 papers, 4.3k citations indexed

About

John Corkery is a scholar working on Toxicology, Clinical Psychology and Cellular and Molecular Neuroscience. According to data from OpenAlex, John Corkery has authored 157 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Toxicology, 52 papers in Clinical Psychology and 33 papers in Cellular and Molecular Neuroscience. Recurrent topics in John Corkery's work include Forensic Toxicology and Drug Analysis (70 papers), Psychedelics and Drug Studies (45 papers) and Neurotransmitter Receptor Influence on Behavior (31 papers). John Corkery is often cited by papers focused on Forensic Toxicology and Drug Analysis (70 papers), Psychedelics and Drug Studies (45 papers) and Neurotransmitter Receptor Influence on Behavior (31 papers). John Corkery collaborates with scholars based in United Kingdom, Italy and Germany. John Corkery's co-authors include Fabrizio Schifano, Amira Guirguis, Stefania Chiappini, Laura Orsolini, A. Hamid Ghodse, Gabriele Duccio Papanti, Adenekan Oyefeso, Giovanni Martinotti, Ornella Corazza and Duccio Papanti and has published in prestigious journals such as SHILAP Revista de lepidopterología, Neuroscience & Biobehavioral Reviews and Psychological Medicine.

In The Last Decade

John Corkery

150 papers receiving 4.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

GLP-1 Receptor Agonists and Related Mental Health Issues; Insights from a Range of Social Media Platforms Using a Mixed-Methods Approach

2023 50 citations Davide Arillotta, Giuseppe Floresta et al. Brain Sciences profile →
Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: Insights from pharmacovigilance measures and unmasking analysis

2024 35 citations Amira Guirguis, Stefania Chiappini et al. European Neuropsychopharmacology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John Corkery United Kingdom	39	1.9k	1.6k	1.0k	853	708	157	4.3k
Adam Winstock United Kingdom	43	1.7k 0.9×	1.9k 1.2×	1.0k 1.0×	1.8k 2.2×	1.7k 2.4×	177	6.0k
Jordi Camı́ Spain	35	1.7k 0.9×	1.3k 0.8×	1.3k 1.3×	1.2k 1.5×	543 0.8×	103	4.1k
Francesco Paolo Busardò Italy	40	2.5k 1.3×	1.0k 0.7×	883 0.9×	1.7k 2.0×	290 0.4×	230	5.2k
Joseph J. Palamar United States	45	1.6k 0.8×	1.6k 1.0×	648 0.6×	1.6k 1.9×	2.0k 2.8×	226	5.7k
Norbert Scherbaum Germany	33	663 0.4×	1.1k 0.7×	673 0.7×	591 0.7×	1.0k 1.4×	286	4.2k
Robert Kronstrand Sweden	39	3.0k 1.6×	1.0k 0.6×	802 0.8×	997 1.2×	263 0.4×	135	4.4k
Roberta Pacifici Italy	50	2.1k 1.1×	1.1k 0.7×	1.1k 1.1×	1.8k 2.1×	481 0.7×	308	8.8k
Bruce A. Goldberger United States	37	1.6k 0.8×	567 0.4×	551 0.5×	959 1.1×	638 0.9×	123	4.2k
Frank Mußhoff Germany	42	2.9k 1.5×	747 0.5×	658 0.6×	1.2k 1.4×	238 0.3×	240	6.5k
Marta Torrens Spain	45	1.8k 0.9×	2.0k 1.3×	1.7k 1.7×	1.9k 2.2×	2.1k 3.0×	282	7.2k

Countries citing papers authored by John Corkery

Since Specialization

Citations

This map shows the geographic impact of John Corkery's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Corkery with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Corkery more than expected).

Fields of papers citing papers by John Corkery

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Corkery. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Corkery. The network helps show where John Corkery may publish in the future.

Co-authorship network of co-authors of John Corkery

This figure shows the co-authorship network connecting the top 25 collaborators of John Corkery. A scholar is included among the top collaborators of John Corkery based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Corkery. John Corkery is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Floresta, Giuseppe, Alberto Granzotto, Vincenzo Patamia, et al.. (2025). Xylazine as an emerging new psychoactive substance; focuses on both 5‐HT₇ and κ‐opioid receptors' molecular interactions and isosteric replacement. Archiv der Pharmazie. 358(3). e2500041–e2500041. 1 indexed citations

Murray, Miranda, et al.. (2025). Potential Eye Disorders in People With and Without Type 2 Diabetes Mellitus Exposed to GLP-1 Receptor Agonists: An Examination of the FAERS (FDA Adverse Event Reporting System) Database. American Journal of Ophthalmology. 283. 279–290.

Corkery, John, et al.. (2025). An Update on Deaths in the United Kingdom from ‘Poppers’ (Alkyl Nitrites), with a Particular Focus on ‘Swallowing’ Fatalities. Journal of Clinical Medicine. 14(2). 427–427. 4 indexed citations

Corkery, John, Caroline S. Copeland, & Fabrizio Schifano. (2025). Deaths related to the use of diarylethylamines, with a focus on the United Kingdom: A systematic review and case series report. Journal of Psychopharmacology. 4126398163–4126398163.

Chiappini, Stefania, Alessio Mosca, Denis Pelletier, et al.. (2025). Adverse Drug Reactions Associated with Concomitant Use of Calcium Channel Blockers and Cocaine: An Analysis of FDA Adverse Events Reporting System Data. Journal of Clinical Medicine. 14(10). 3461–3461.

Corkery, John, et al.. (2025). Deaths following illicit ketamine use in England, Wales and Northern Ireland 1999–2024: An update report to inform the reclassification debate. Journal of Psychopharmacology. 4126422018–4126422018.

Santo, Riccardo Di, Gabriele Ciasca, John Corkery, et al.. (2024). Postmortem findings of organ damage in novel psychoactive substances users: A comprehensive review. Neuroscience & Biobehavioral Reviews. 167. 105927–105927. 1 indexed citations

Guirguis, Amira, Stefania Chiappini, Rachel Vickers‐Smith, et al.. (2024). Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: Insights from pharmacovigilance measures and unmasking analysis. European Neuropsychopharmacology. 82. 82–91. 35 indexed citations breakdown →

Floresta, Giuseppe, Davide Arillotta, Valeria Catalani, et al.. (2024). Semaglutide as a Possible Calmodulin Binder: Ligand-Based Computational Analyses and Relevance to Its Associated Reward and Appetitive Behaviour Actions. Scientia Pharmaceutica. 92(2). 17–17. 1 indexed citations

10.

Chiappini, Stefania, Alessio Mosca, Andrea Miuli, et al.. (2022). Misuse of Anticholinergic Medications: A Systematic Review. Biomedicines. 10(2). 355–355. 16 indexed citations

11.

Chiappini, Stefania, Rachel Vickers‐Smith, Amira Guirguis, et al.. (2022). Pharmacovigilance Signals of the Opioid Epidemic over 10 Years: Data Mining Methods in the Analysis of Pharmacovigilance Datasets Collecting Adverse Drug Reactions (ADRs) Reported to EudraVigilance (EV) and the FDA Adverse Event Reporting System (FAERS). Pharmaceuticals. 15(6). 675–675. 21 indexed citations

12.

Corkery, John, et al.. (2021). Recreational ketamine-related deaths notified to the National Programme on Substance Abuse Deaths, England, 1997–2019. Journal of Psychopharmacology. 35(11). 1324–1348. 32 indexed citations

13.

Guirguis, Amira, et al.. (2020). Exploring the Baseline Knowledge and Experience of Healthcare Professionals in the United Kingdom on Novel Psychoactive Substances. Brain Sciences. 10(3). 142–142. 10 indexed citations

14.

Chiappini, Stefania, Fabrizio Schifano, John Corkery, & Amira Guirguis. (2020). Focus on Clozapine Withdrawal- and Misuse-Related Cases as Reported to the European Medicines Agency (EMA) Pharmacovigilance Database. Brain Sciences. 10(2). 105–105. 24 indexed citations

15.

Schifano, Fabrizio, Flavia Napoletano, Davide Arillotta, et al.. (2019). The clinical challenges of synthetic cathinones. British Journal of Clinical Pharmacology. 86(3). 410–419. 49 indexed citations

16.

Corkery, John, Fabrizio Schifano, & Giovanni Martinotti. (2019). How deaths can help clinicians and policy‐makers understand the risks of novel psychoactive substances. British Journal of Clinical Pharmacology. 86(3). 482–498. 27 indexed citations

17.

Corkery, John, Peter Streete, Hugh Claridge, et al.. (2019). Characteristics of deaths associated with kratom use. Journal of Psychopharmacology. 33(9). 1102–1123. 77 indexed citations

18.

Corkery, John, et al.. (2019). Impact of the UK Psychoactive Substances Act on awareness, use, experiences and knowledge of potential associated health risks of novel psychoactive substances. British Journal of Clinical Pharmacology. 86(3). 505–516. 12 indexed citations

19.

Loi, Barbara, Mire Zloh, Maria Antonietta De Luca, et al.. (2017). 4,4′‐Dimethylaminorex (“4,4′‐DMAR”; “Serotoni”) misuse: A Web‐based study. Human Psychopharmacology Clinical and Experimental. 32(3). 14 indexed citations

20.

Corkery, John, et al.. (1987). Prospective trial of operative versus non-operative treatment of severe vesicoureteric reflux in children: five years' observation. Birmingham Reflux Study Group.. BMJ. 295(6592). 237–241. 166 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact